Beranda › Gangguan Depresi Mayor › Alabama
Uji klinis Gangguan Depresi Mayor di Alabama
15 studi untuk Gangguan Depresi Mayor mencari peserta di lokasi di Alabama.
Kota di Alabama
Teks studi resmi (Bahasa Inggris)
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 3
Usia 12 hingga 17 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
Menerima peserta
Usia 22 hingga 70 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
Menerima pesertaSukarelawan sehat diterima
Usia 10 hingga 24 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
Menerima peserta
Usia 25 hingga 50 · Semua jenis kelamin · Diperbarui 3 Mar 2026 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06633016Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.